(Press-News.org) In the constant cross talk between our brain and our gut, two gut hormones are already known to tell the brain when we have had enough to eat. New research suggests that boosting levels of these hormones simultaneously may be an effective new weapon in the fight against obesity.
Dr Shu Lin, Dr Yan-Chuan Shi and Professor Herbert Herzog, from Sydney's Garvan Institute of Medical Research, have shown that when mice are injected with PYY3-36 and PP, they eat less, gain less fat, and tend not to develop insulin-resistance, a precursor to diabetes. At the same time, the researchers have shown that the hormones stimulate different nerve pathways, ultimately, however, affecting complementary brain regions. Their findings are now published online in the journal Obesity.
While the double-barreled approach may seem like a no-brainer, the strongly enhanced effect seen was by no means inevitable. In the complex world of neuroscience, two plus two does not always make four.
Drug companies are in the process of conducting pre-clinical trials to examine the separate effects of boosting the hormones PYY3-36 and PP. Until now, there is no research to indicate the detailed molecular interactions that might occur when they are boosted in tandem.
When used together, the hormones independently, yet with combined force, reduce the amount of neuropeptide Y (NPY) produced by the brain, a powerful neurotransmitter that affects a variety of things including appetite, mood, heart rate, temperature and energy levels.
Each hormone also communicates with a different part of the arcuate nucleus in the hypothalamus, a region of the brain where signals can cross the normally impermeable blood / brain barrier. The stimulated regions then produce other neuronal signals deep within the hypothalamus, bringing about a powerful combined effect.
"There are many factors that influence appetite control – and we now realise that there won't be a single molecular target, or a single drug, that will be effective," said Dr Yan-Chuan Shi.
"It will be important for drug companies to try different combinations of targets, to see which combinations are most potent, and at the same time have no side effects, or at least minimal side effects."
"At the moment, the only effective tool against obesity is surgery. Drug companies have so far failed to produce an effective drug without unacceptable side effects, such as mood disorders, nausea or cardiovascular problems."
INFORMATION:
Double-barreled attack on obesity in no way a no-brainer
2013-07-09
ELSE PRESS RELEASES FROM THIS DATE:
Graphene on its way to conquer Silicon Valley
2013-07-09
The unique properties of graphene such as its incredible strength and, at the same time, its little weight have raised high expectations in modern material science. Graphene, a two-dimensional crystal of carbon atoms packed in a honeycomb structure, has been in the focus of intensive research which led to a Nobel Prize of Physics in 2010. One major challenge is to successfully integrate graphene into the established metal-silicide technology. Scientists from the University of Vienna and their co-workers from research institutes in Germany and Russia have succeeded in fabricating ...
Technologies for monitoring remaining leukemia after treatment may help predict patient outcomes
2013-07-09
(WASHINGTON, July 9, 2013) – New evidence suggests that using advanced genetics technologies to monitor for remaining cancer cells after treatment may soon become an effective tool to inform treatment decisions and ultimately predict patient outcomes for patients with a particularly aggressive form of acute lymphocytic leukemia (ALL). Study results were published online today in Blood, the Journal of the American Society of Hematology (ASH).
Approximately 25 to 30 percent of all adults with ALL, the second most common type of acute leukemia, have what is known as Philadelphia ...
Are clinical trial data shared sufficiently today?
2013-07-09
Ben Goldacre, research fellow at the London School of Hygiene and Tropical Medicine, says we need all the evidence to make informed decisions about medicines.
The lack of progress on transparency has been startling, he writes. Current estimates suggest that around half of all trials for the treatments being used today have gone unpublished; and that trials with positive results are twice as likely to be published.
There is legislation mandating greater transparency – such as the law requiring trial results to be posted on the website clinicaltrials.gov – but the published ...
Suspicions confirmed: Brain tumors in children have a common cause
2013-07-09
Brain cancer is the primary cause of cancer mortality in children. Even in cases when the cancer is cured, young patients suffer from the stress of a treatment that can be harmful to the developing brain. In a search for new target structures that would create more gentle treatments, cancer researchers are systematically analyzing all alterations in the genetic material of these tumors. This is the mission of the PedBrain consortium, which was launched in 2010. Led by Professor Stefan Pfister from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), ...
GR20/Amaldi10: Space-time is not the same for everyone
2013-07-09
Before the Big Bang, space-time as we know it did not exist. So how was it born? The process of creating normal space-time from an earlier state dominated by quantum gravity has been studied for years by theorists at the Faculty of Physics, University of Warsaw. Recent analyses suggest a surprising conclusion: not all elementary particles are subject to the same space-time.
Several billion years ago, in the era soon after the Big Bang, the Universe was so dense and so hot that elementary particles felt the existence of gravity strongly. For decades, physicists around ...
RUB researchers decode the interplay between enkephalins and pain receptors
2013-07-09
"Pain begone!" In order to send out this signal, the human body produces tiny messenger molecules that dock to certain receptors. Using traditional biochemical methods, this interaction between the messengers, so-called enkephalins, and opioid receptors is very difficult to study. An interdisciplinary team of biochemists and inorganic chemists at the Ruhr-Universität Bochum (RUB) has now succeeded in identifying the structure of an enkephalin in solution and to track its interaction with the opioid receptor in detail. The analysis provides a new, precise starting point ...
Researchers build 3-D structures out of liquid metal
2013-07-09
Researchers from North Carolina State University have developed three-dimensional (3-D) printing technology and techniques to create free-standing structures made of liquid metal at room temperature.
"It's difficult to create structures out of liquids, because liquids want to bead up. But we've found that a liquid metal alloy of gallium and indium reacts to the oxygen in the air at room temperature to form a 'skin' that allows the liquid metal structures to retain their shapes," says Dr. Michael Dickey, an assistant professor of chemical and biomolecular engineering at ...
Big name for a small worm
2013-07-09
This news release is available in German. An unusual posthumous honour for physicist Max Planck: Biologists in Tübingen working with Ralf J. Sommer have named a newly discovered nematode after the German Nobel laureate. Pristionchus maxplancki is thus the first species to carry the name of the scientist, who died in 1947. The discovery from the Far East is assisting the researchers of the Max Planck Institute for Developmental Biology to attain new insights and knowledge about the many interdependencies between evolution, genetics, and ecology.
When Japanese biologist ...
Contaminated ultrasound gel tied to outbreak of healthcare-associated infections
2013-07-09
CHICAGO (July 9, 2013) – After a 2011 outbreak of P. aeruginosa, investigators at Beaumont Health System near Detroit, Michigan determined contaminated ultrasound gel was the source of bacteria causing the healthcare-associated infection. The findings emphasize the need for increased scrutiny of contaminated medical products. This study is published in the August issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.
"Ultrasound is a critical healthcare tool used every day in both diagnostic and interventional ...
Sanford-Burnham researchers develop novel nanoparticle to deliver powerful RNA interference drugs
2013-07-09
LA JOLLA, Calif., July 8 2013 – Silencing genes that have malfunctioned is an important approach for treating diseases such as cancer and heart disease. One effective approach is to deliver drugs made from small molecules of ribonucleic acid, or RNA, which are used to inhibit gene expression. The drugs, in essence, mimic a natural process called RNA interference.
In a new paper appearing today online in the journal, ACS Medicinal Chemistry Letters, researchers at Sanford-Burnham Medical Research Institute have developed nanoparticles that appear to solve a big challenge ...